Сообщения

Data Published in The Lancet Shows High Efficacy at 96 Weeks for...

Data Published in The Lancet Shows High Efficacy at 96 Weeks for...
CORK, Ireland, July 24: Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson and Johnson today announced that a regimen of two investigational long-acting, injectable formulations of HIV medicines -Janssen's rilpivirine and ViiV Healthcare's cabotegravir - given together every 4 or 8 weeks was as effective as 3-drug oral antiretroviral therapy at maintaining HIV-1 viral suppression through 96 weeks receiving injections every eight weeks, warranting further investigation. Virologic response was also achieved by 87 percent of those receiving injections every four weeks versus 84 percent receiving oral ART therapy.

from Biotech News

Girl's HIV infection seems under control without AIDS drugs

Girl's HIV infection seems under control without AIDS drugs
This undated photo provided by the Centers for Disease Control and Prevention shows a scanning electron micrograph of multiple round bumps of the HIV-1 virus on a cell surface. In a report released on Monday, July 24, 2017, researchers said a South African girl born with the AIDS virus has kept her infection suppressed for 8 1/2 years after stopping anti-HIV medicines _ more evidence that early treatment can occasionally cause a long remission that, if it lasts, would be a form of cure.

from Biotech News

Bayer erhält Empfehlung für erweiterte Xarelto-Zulassung in Europa

Bayer erhält Empfehlung für erweiterte Xarelto-Zulassung in Europa
(dpa-AFX) Der Pharmakonzern Bayer hat für seinen Kassenschlager Xarelto eine Empfehlung für eine erweiterte Zulassung in Europa erhalten. Ein Komitee der europäischen Zulassungsbehörde EMA sprach sich dafür aus, dass der Blutgerinnungshemmer künftig auch bei bestimmten Patienten nach der Behandlung ...

from bionity.com News | Ein Übersichtsbeitrag über Goldankauf in Berlin, Germany.